SILVER SPRING
Caplyta sNDA approved for schizophrenia relapse risk reduction
- Sponsor
- Johnson & Johnson $JNJ
- Drug
- Caplyta · lumateperone
- Indication
- schizophrenia
FDA approved a supplemental New Drug Application for Caplyta (lumateperone) based on long-term data supporting reduced relapse risk in schizophrenia.
What this means
Caplyta is an antipsychotic drug that helps regulate brain chemicals involved in schizophrenia symptoms. Today FDA approved Caplyta for reducing the risk of relapse in schizophrenia, based on long-term safety and effectiveness data. This decision gives patients and doctors a new option to help maintain stability and prevent symptom return in this chronic mental health condition.
Drug Watch — recent news on Caplyta
- Lumateperone Improves Acute Mania Symptoms, Trial Results Presented at Psych Congress - HMP Global Learning Network
- Drug Improves Sexual Function for Depression Patients, Study Finds - UVA Health
- Could Lumateperone Be the Key to Improving Sexual Function During Depression Treatment? - JO24
- J&J Slips as Caplyta Clears a Quality-of-Life Test - Yahoo! Finance Canada
- Fewer Americans say measles vaccines are safe for kids; cardiovascular disease now kills more Hispanic adults than cancer; lumateperone and sexual function in depression — Morning Medical Update - Medical Economics